<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.1?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="iso-abbrev">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="publisher-id">nar</journal-id>
    <journal-title-group>
      <journal-title>Nucleic Acids Research</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">0305-1048</issn>
    <issn pub-type="epub">1362-4962</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">8128064</article-id>
    <article-id pub-id-type="pmid">33885790</article-id>
    <article-id pub-id-type="doi">10.1093/nar/gkab278</article-id>
    <article-id pub-id-type="publisher-id">gkab278</article-id>
    <article-categories>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI00010</subject>
      </subj-group>
      <subj-group subj-group-type="heading">
        <subject>Web Server Issue</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>Arena3D<sup>web</sup>: interactive 3D visualization of multilayered networks</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Karatzas</surname>
          <given-names>Evangelos</given-names>
        </name>
        <!--karatzas@fleming.gr-->
        <aff><institution>Institute for Fundamental Biomedical Research</institution>, BSRC “Alexander Fleming”, Vari, <country country="GR">Greece</country></aff>
        <xref rid="COR2" ref-type="corresp"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Baltoumas</surname>
          <given-names>Fotis A</given-names>
        </name>
        <aff><institution>Institute for Fundamental Biomedical Research</institution>, BSRC “Alexander Fleming”, Vari, <country country="GR">Greece</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Panayiotou</surname>
          <given-names>Nikolaos A</given-names>
        </name>
        <aff><institution>School of Mechanical Engineering, Section of Industrial Management and Operational Research, National Technical University of Athens</institution>, Zografou, Athens, <country country="GR">Greece</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8278-1618</contrib-id>
        <name>
          <surname>Schneider</surname>
          <given-names>Reinhard</given-names>
        </name>
        <aff><institution>University of Luxembourg, Luxembourg Centre for Systems Biomedicine</institution>, Bioinformatics Core, Esch-sur-Alzette, <country country="LU">Luxembourg</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4577-8276</contrib-id>
        <name>
          <surname>Pavlopoulos</surname>
          <given-names>Georgios A</given-names>
        </name>
        <!--pavlopoulos@fleming.gr-->
        <aff><institution>Institute for Fundamental Biomedical Research</institution>, BSRC “Alexander Fleming”, Vari, <country country="GR">Greece</country></aff>
        <xref rid="COR1" ref-type="corresp"/>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="COR1">To whom correspondence should be addressed. Tel: +30 210 9656310; Fax: +30 210 9653934; Email: <email>pavlopoulos@fleming.gr</email></corresp>
      <corresp id="COR2">Correspondence may also be addressed to Evangelos Karatzas. Email: <email>karatzas@fleming.gr</email></corresp>
    </author-notes>
    <pub-date pub-type="collection">
      <day>02</day>
      <month>7</month>
      <year>2021</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2021-04-22">
      <day>22</day>
      <month>4</month>
      <year>2021</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>22</day>
      <month>4</month>
      <year>2021</year>
    </pub-date>
    <volume>49</volume>
    <issue>W1</issue>
    <fpage>W36</fpage>
    <lpage>W45</lpage>
    <history>
      <date date-type="accepted">
        <day>08</day>
        <month>4</month>
        <year>2021</year>
      </date>
      <date date-type="rev-recd">
        <day>23</day>
        <month>3</month>
        <year>2021</year>
      </date>
      <date date-type="received">
        <day>11</day>
        <month>1</month>
        <year>2021</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2021. Published by Oxford University Press on behalf of Nucleic Acids Research.</copyright-statement>
      <copyright-year>2021</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact <email>journals.permissions@oup.com</email></license-p>
      </license>
    </permissions>
    <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="gkab278.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p>Efficient integration and visualization of heterogeneous biomedical information in a single view is a key challenge. In this study, we present Arena3D<sup>web</sup>, the first, fully interactive and dependency-free, web application which allows the visualization of multilayered graphs in 3D space. With Arena3D<sup>web</sup>, users can integrate multiple networks in a single view along with their intra- and inter-layer connections. For clearer and more informative views, users can choose between a plethora of layout algorithms and apply them on a set of selected layers either individually or in combination. Users can align networks and highlight node topological features, whereas each layer as well as the whole scene can be translated, rotated and scaled in 3D space. User-selected edge colors can be used to highlight important paths, while node positioning, coloring and resizing can be adjusted on-the-fly. In its current version, Arena3D<sup>web</sup> supports weighted and unweighted undirected graphs and is written in R, Shiny and JavaScript. We demonstrate the functionality of Arena3D<sup>web</sup> using two different use-case scenarios; one regarding drug repurposing for SARS-CoV-2 and one related to GPCR signaling pathways implicated in melanoma. Arena3D<sup>web</sup> is available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://bib.fleming.gr:3838/Arena3D" ext-link-type="uri">http://bib.fleming.gr:3838/Arena3D</ext-link> or <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://bib.fleming.gr/Arena3D" ext-link-type="uri">http://bib.fleming.gr/Arena3D</ext-link>.</p>
    </abstract>
    <abstract abstract-type="graphical">
      <title>Graphical Abstract</title>
      <p>
        <fig position="float" id="ga1">
          <label>Graphical Abstract</label>
          <caption>
            <p>Arena3D<sup>web</sup>: interactive 3D visualization of multilayered networks.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="gkab278gra1" position="float"/>
        </fig>
      </p>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Hellenic Foundation for Research and Innovation</institution>
            <institution-id institution-id-type="DOI">10.13039/501100013209</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>1855-BOLOGNA</award-id>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="10"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="SEC1">
    <title>INTRODUCTION</title>
    <p>Simple networks are often used to model relationships between entities in real‐world systems. Typical examples of such networks in the biomedical field are the gene co-expression networks, sequence similarity networks (SSNs), protein–protein interaction networks (PPIs), metabolic networks, signal transduction networks, gene regulatory networks, gene–disease networks, evolution networks, bipartite graphs, food webs and others (<xref rid="B1" ref-type="bibr">1</xref>). Most of these networks come with certain topological features and fall into one of the Erdos–Rényi (random), Watts-Strogatz (small-word) and Barabási–Albert (scale-free) categories (<xref rid="B2" ref-type="bibr">2</xref>). Efficient visualizers take advantage of these topological properties and utilize advanced graph-drawing (layout) algorithms (e.g. force-directed, hierarchical, orthogonal and spectral) to generate informative and appealing 2D/3D views thus minimizing any possible node overlaps and connection crossovers (<xref rid="B3" ref-type="bibr">3</xref>). Among a decent variety of applications today (<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B5" ref-type="bibr">5</xref>), widely-used interactive 2D visualizers include the Cytoscape (<xref rid="B6" ref-type="bibr">6</xref>), Cytoscape.js (<xref rid="B7" ref-type="bibr">7</xref>), String (<xref rid="B8" ref-type="bibr">8</xref>), NORMA (<xref rid="B9" ref-type="bibr">9</xref>), Gephi (<xref rid="B10" ref-type="bibr">10</xref>), Pajek (<xref rid="B11" ref-type="bibr">11</xref>) and Tulip (<xref rid="B12" ref-type="bibr">12</xref>) whereas successful 3D visualizers include the Graphia (Kajeka) and BioLayout Express (<xref rid="B13" ref-type="bibr">13</xref>).</p>
    <p>Despite the great functionality and interactivity of these viewers, most of them currently offer over-simplified views and often fail to capture patterns in today's data heterogeneity and complexity. In the biomedical field for example, a new trend is to integrate heterogeneous information from various repositories in a single view or support experimental findings (e.g. biomarker detection) in multiple ways (e.g. genomics, proteomics, metabolomics). Therefore, visualizers able to offer a more structured analysis along with contemporary multilayer network visualization are necessary (<xref rid="B14" ref-type="bibr">14</xref>). While this area of network analysis is still in its infancy, few implementations in this direction have been already proposed. The Arena3D standalone version (<xref rid="B15" ref-type="bibr">15</xref>,<xref rid="B16" ref-type="bibr">16</xref>), for example, enables an interactive multilayered graph visualization but is poor in the inter/intra-layer layouts that it offers. Pymnet is a python library which can produce high quality static images of multilayer and multiplex networks and therefore, familiarity with Python programming language is required. Similarly, Py3plex (<xref rid="B17" ref-type="bibr">17</xref>) a python library, which handles multilayered networks and enables common operations such as aggregation, slicing, indexing and traversal but lacks interactivity and fails to solve the edge overlapping problem. Mully (<xref rid="B18" ref-type="bibr">18</xref>) is an R package to create, modify and visualize multilayered graphs but lacks interactivity too. Finally, MuxViz (<xref rid="B19" ref-type="bibr">19</xref>) is a framework which is more suitable for layer analysis and visualization of geospatial data.</p>
    <p>In this article, we propose Arena3D<sup>web</sup>, the first web application which offers a fully interactive 3D visualization and analysis of multilayered networks. Arena3D<sup>web</sup> comes with many inter/intra-layer layouts and network metrics for node scaling, is dependency-free and is easily accessible to non-experts from a web browser. It is written in R, Shiny and JavaScript whereas the backend calculations are based on the igraph library (<xref rid="B20" ref-type="bibr">20</xref>). We believe that Arena3D<sup>web</sup> is a general-purpose tool which can successfully address many of the complexity issues in the biomedical field and can offer informative and appealing visualizations suitable for knowledge integration, representation, transfer and communication.</p>
  </sec>
  <sec sec-type="materials|methods" id="SEC2">
    <title>MATERIALS AND METHODS</title>
    <sec id="SEC2-1">
      <title>Input and export files</title>
      <p>In its current version, Arena3D<sup>web</sup> mainly accepts three different types of tab-delimited files as input. The main file is a four- or a five-column file describing the network in a simple format like: <italic toggle="yes">node</italic><inline-formula><tex-math id="M1">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$i$\end{document}</tex-math></inline-formula><italic toggle="yes">from layer</italic><inline-formula><tex-math id="M2">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$x$\end{document}</tex-math></inline-formula><italic toggle="yes">is connected to node</italic><inline-formula><tex-math id="M3">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$j$\end{document}</tex-math></inline-formula><italic toggle="yes">from layer</italic><inline-formula><tex-math id="M4">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$y$\end{document}</tex-math></inline-formula>. In the case of a weighted graph, weights can be added as an extra column. In addition to the main file, users are allowed to upload two more files with further information about the node and edge attributes. In the first case, nodes can be accompanied by a URL, a description, a color, and a custom size whereas in the second case, edges can be accompanied by a color. For convenience, the column order in any of the aforementioned files is insignificant as long as headers are used strictly. Notably, users can save and export the status of a network at any time in an Arena3D<sup>web</sup> file format. This file contains all the necessary information from nodes and connections to colors and 3D coordinates. It is a text file format which users can modify manually at any time. Notably, directed networks are not handled differently by the current version of Arena3D<sup>web</sup>.</p>
    </sec>
    <sec id="SEC2-2">
      <title>Graph drawing and layouts</title>
      <p>As a default option, Arena3D<sup>web</sup> places all uploaded layers in parallel and spreads them horizontally. Once the main network has been loaded and rendered, users can choose between a variety of layout algorithms to adjust the node coordinates. By applying a layout algorithm on a selected layer or a set of selected layers individually, users can eliminate the intra-layer line crossovers without impacting the inter-layer connections. On the contrary, when users decide to apply a layout algorithm on a set of selected layers in combination, then more focus is given on eliminating the inter-layer crossovers. In the second case, the layout algorithm will handle all nodes from the selected layers and their connections as one unified network and will place them back on their originating layers once the layout algorithm has converged. The latter is a powerful feature for creating network pseudo-alignments (Figure <xref rid="F1" ref-type="fig">1</xref>, layers 5 and 6) and generating appealing and informative views. Finally, users are allowed to apply any of the offered layout algorithms locally on a set of selected nodes per layer.</p>
      <fig position="float" id="F1">
        <label>Figure 1.</label>
        <caption>
          <p>Random networks with different topologies were drawn with the use of various layout algorithms supported by igraph and subsequently by Arena3D<sup>web</sup>. Nodes on layer 1 are placed on a grid. Nodes on layer 2 have been placed in a hierarchy using the Reingold–Tilford layout algorithm. Nodes on the first two layers are scaled based on degree. Layer 3 shows a small-world network drawn using the Kamada–Kawai layout algorithm. Layer 4 shows a scale-free network also drawn with the Kamada–Kawai layout algorithm. Nodes on layers 3 and 4 are scaled based on their clustering coefficient. Layers 5 and 6 have been combined and are drawn using the Fruchterman–Reingold layout algorithm. Both layers were handled as a unified network and nodes were placed back to their layers after the completion of the layout algorithm, thus giving a sense of a network alignment. The node scale of these two layers is relative to their degree.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="gkab278fig1" position="float"/>
      </fig>
      <p>In this version, Arena3D<sup>web</sup> supports a variety of layout algorithms implemented as part of the R/igraph library (<xref rid="B20" ref-type="bibr">20</xref>). Briefly, these are:</p>
      <list list-type="bullet">
        <list-item>
          <p><italic toggle="yes">Circle</italic>: It is a simple layout and places the vertices on a circle, ordered by their vertex ids.</p>
        </list-item>
        <list-item>
          <p><italic toggle="yes">Grid</italic>: This simple layout places vertices on a rectangular 2D grid.</p>
        </list-item>
        <list-item>
          <p><italic toggle="yes">Random</italic>: This function places the vertices of the graph on a 2D plane uniformly using random coordinates.</p>
        </list-item>
        <list-item>
          <p><italic toggle="yes">Star</italic>: It places the vertices of a graph on the plane, according to the simulated annealing algorithm developed by Davidson and Harel. It is a simple layout generator that places one vertex in the center of a circle and the rest of the vertices equidistantly on the perimeter.</p>
        </list-item>
        <list-item>
          <p><italic toggle="yes">Reingold-Tilford</italic> (<xref rid="B21" ref-type="bibr">21</xref>): It is a tree-like layout more suitable for trees, hierarchies and graphs without many cycles.</p>
        </list-item>
        <list-item>
          <p><italic toggle="yes">Sugiyama</italic>: Like Reingold–Tilford, this layout algorithm is more suitable for hierarchies and layered directed acyclic graphs.</p>
        </list-item>
        <list-item>
          <p><italic toggle="yes">Fruchterman–Reingold</italic> (<xref rid="B22" ref-type="bibr">22</xref>): It places nodes on the plane using the force-directed layout algorithm developed by Fruchterman and Reingold.</p>
        </list-item>
        <list-item>
          <p><italic toggle="yes">Davidson–Harel</italic> (<xref rid="B23" ref-type="bibr">23</xref>): It is a force-directed algorithm, which uses simulated annealing and a sophisticated energy function to place nodes on a plane.</p>
        </list-item>
        <list-item>
          <p><italic toggle="yes">Distributed Recursive (Graph) Layout</italic> (<xref rid="B24" ref-type="bibr">24</xref>): DrL is a force-directed graph layout toolbox focused on real-world large-scale graphs.</p>
        </list-item>
        <list-item>
          <p><italic toggle="yes">Multidimensional scaling</italic> (<xref rid="B25" ref-type="bibr">25</xref>): It aims to place points from a higher dimensional space on a 2D plane, so that the distance between the points is kept as much as possible.</p>
        </list-item>
        <list-item>
          <p><italic toggle="yes">Kamada–Kawai</italic> (<xref rid="B26" ref-type="bibr">26</xref>): This force-directed layout places the vertices on a 2D plane by simulating a physical model of springs.</p>
        </list-item>
        <list-item>
          <p><italic toggle="yes">Large Graph Layout (LGL)</italic>: A force-directed layout suitable for larger graphs.</p>
        </list-item>
        <list-item>
          <p><italic toggle="yes">Graphopt</italic>: A force-directed layout algorithm, which scales relatively well to large graphs.</p>
        </list-item>
        <list-item>
          <p><italic toggle="yes">Gem</italic> (<xref rid="B27" ref-type="bibr">27</xref>): It places vertices on the plane using the GEM force-directed layout algorithm.</p>
        </list-item>
      </list>
      <p>In Figure <xref rid="F1" ref-type="fig">1</xref>, we show representative views which demonstrate some of the aforementioned functionalities. Nodes on the first layer have been placed on a simple grid whereas node coordinates on the second layer (random acyclic graph) have been generated by the Reingold–Tilford layout. The force-directed Kamada-Kawai layout algorithm has been applied separately on a small-world and a scale-free random network on layers 3 and 4 accordingly. Finally, networks on layers 5 and 6 have been treated as one unified network aligned with the use of the Fruchterman–Reingold force-directed algorithm.</p>
    </sec>
    <sec id="SEC2-3">
      <title>Topological features</title>
      <p>Nodes on a set of selected layers can be resized according to topological properties such as the <italic toggle="yes">degree</italic>, <italic toggle="yes">clustering coefficient</italic> and <italic toggle="yes">betweenness centrality</italic>. For example, nodes with higher connectivity degrees can be forced to appear larger. This function can be performed on each of the selected layers individually or in combination. In the first case, only the intra-layer connections are taken into account whereas in the second case both the intra- and inter-layer connections are considered. Briefly, as <italic toggle="yes">degree</italic><inline-formula><tex-math id="M5">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$de{g_i}$\end{document}</tex-math></inline-formula>, we define the total number of connections adjacent to a node <inline-formula><tex-math id="M6">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$i$\end{document}</tex-math></inline-formula>. The <italic toggle="yes">clustering coefficient</italic> of a node <inline-formula><tex-math id="M7">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$i$\end{document}</tex-math></inline-formula> shows whether this node has the tendency to form clusters and is defined as the number of edges between a node's neighbors divided by the number of all possible connections between these neighbors. The <italic toggle="yes">betweenness centrality</italic> highlights nodes which can act as mediators in order for two communities to communicate with each other. It is calculated as <inline-formula><tex-math id="M8">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${B_i} = \frac{{{\sigma _{xy}}( i )}}{{{\sigma _{xy}}}}\;$\end{document}</tex-math></inline-formula> where <inline-formula><tex-math id="M9">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\sigma _{xy}}$\end{document}</tex-math></inline-formula> is the total number of shortest paths from node <inline-formula><tex-math id="M10">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$x$\end{document}</tex-math></inline-formula> to node <inline-formula><tex-math id="M11">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$y$\end{document}</tex-math></inline-formula> and <inline-formula><tex-math id="M12">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\sigma _{xy}}( i )$\end{document}</tex-math></inline-formula> is the number of those paths that pass through the node <inline-formula><tex-math id="M13">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$i$\end{document}</tex-math></inline-formula>. For demonstration purposes, in Figure <xref rid="F1" ref-type="fig">1</xref>, nodes on layers 1 and 2 have been resized based on their connectivity degree. Nodes on layers 3 and 4 have been resized based on their clustering coefficient. Finally, nodes on layers 5 and 6 have been resized based on their degree, while considering both layers as one unified network.</p>
    </sec>
    <sec id="SEC2-4">
      <title>Navigation controls</title>
      <p>Arena3D<sup>web</sup> comes with various control buttons for easy 3D navigation (Figure <xref rid="F2" ref-type="fig">2</xref>). These buttons are grouped in three main categories. These are: (i) buttons for the whole scene, (ii) buttons for each layer, (iii) buttons for the nodes within a layer.</p>
      <fig position="float" id="F2">
        <label>Figure 2.</label>
        <caption>
          <p>Random networks visualized by Arena3D<sup>web</sup>. (<bold>A</bold>) Layers 1–4 are placed in a 3D cube. Node sizes on layers 1 and 2 are adjusted by connectivity degree, nodes on layer 3 by betweenness centrality and nodes on layer 4 by clustering coefficient. The Kamada Kawai layout algorithm has been applied on each layer individually. First neighbors of a node and their connections are colored yellow. (<bold>B</bold>) Layers 1–3 host three different scale-free random networks whereas layer 4 hosts a small-world random network. Based on a node attributes file, nodes with higher connectivity degree are resized and colored red, green, purple and yellow. Based on an edge attributes file, the inter-layer edges of the upscaled nodes are colored red, green, blue and yellow. The Fruchterman–Reingold layout algorithm has been applied on each layer individually.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="gkab278fig2" position="float"/>
      </fig>
      <sec id="SEC2-4-1">
        <title>The scene</title>
        <p>Arena3D<sup>web</sup> uses a global cartesian coordinate system and adopts the red green and blue colors to highlight the <italic toggle="yes">x</italic>, <italic toggle="yes">y</italic> and <italic toggle="yes">z</italic> axes accordingly. The whole network can be rotated clockwise and counter-clockwise around any on the three axes using the navigation buttons. The rotation angle and subsequently the rotation speed can be adjusted manually. Zooming, panning and orbiting are controlled by mouse events as well as by keyboard strokes.</p>
      </sec>
      <sec id="SEC2-4-2">
        <title>The layer</title>
        <p>In Arena3D<sup>web</sup>, each layer comes with its own individual coordinate system. Users are allowed to rotate and translate any layer around any of the <italic toggle="yes">x</italic>, <italic toggle="yes">y</italic>, <italic toggle="yes">z</italic> axes and place them anywhere in 3D space. In the case where multiple layers have been selected, each transformation will be applied to each of them individually. Like before, the rotation angle as well as the translation step can be adjusted manually. In addition, each layer floor can be scaled up or down by a user-defined factor and node coordinates on the corresponding layer will be adjusted automatically. Finally, to avoid incomprehensive views when layers are placed too close to each other, users have the option to expand or collapse the view by adjusting their in-between distance.</p>
      </sec>
      <sec id="SEC2-4-3">
        <title>The nodes</title>
        <p>Nodes can be placed anywhere on a plane regardless the position and orientation of the layer. Users can select a single node or multiple nodes simultaneously using a rectangle selection and translate them in 3D space. To cope with node and label overlapping problems, users can apply any of the offered layout algorithms locally on a set of selected nodes or increase and decrease their local coordinates thus giving the feeling of repulsion or attraction. Like before, the translation step can be manually adjusted. Finally, node sizes can be scaled manually with the use of a slide bar.</p>
      </sec>
    </sec>
    <sec id="SEC2-5">
      <title>Styles and colors</title>
      <p>Arena3D<sup>web</sup> comes with a plethora of options to avoid incomprehensive visualizations. Users can show and hide the labels of each layer as well as the layer itself along with the corresponding connections. Similarly, users can show and hide the coordinate system of the whole scene as well as the coordinate systems of each individual layer. Nodes and edges can be manually colored to highlight important paths whereas edge weights are represented by an edge's opacity. The lower the weight, the more transparent the edge's color and vice versa. The background color as well as each layer's floor color can be changed with the use of a color picker whereas each floor's transparency can be adjusted manually. Finally, the inter-layer and the intra-layer connection opacities can be adjusted. This way, one can emphasize on the intra- or the inter-layer edges separately. Finally, Arena3D<sup>web</sup> gives the option to highlight the first-neighbors of a node along with their corresponding connections or highlight the paths that this node is involved in across all layers.</p>
    </sec>
    <sec id="SEC2-6">
      <title>Implementation</title>
      <p>Arena3D<sup>web</sup> is mainly written in R and JavaScript programming languages. Its frontend is written using the R/Shiny package, HTML, CSS and JavaScript. The Shiny package was used as the mediator to establish the communication between the R and JavaScript variables and functions. In the backend, the <italic toggle="yes">igraph</italic> library was used for all network layout algorithms as well as for the calculation of the topological metrics used for node scaling. 3D graphics in the main view were handled by the three.js JavaScript library. The library uses the WebGL JavaScript API for graphics and 3D object rendering.</p>
    </sec>
  </sec>
  <sec sec-type="results" id="SEC3">
    <title>RESULTS</title>
    <p>In order to demonstrate how Arena3D<sup>web</sup> can visualize heterogeneous complex information in real case scenarios, we provide two examples, the one related to drug repurposing for SARS-CoV-2 (network with 456 nodes and 985 edges) and the other related to GPCR signaling pathways implicated in melanoma (network with 64 nodes and 332 edges).</p>
    <sec id="SEC3-1">
      <title>Drug repurposing for SARS-CoV-2: a case study</title>
      <p>SARS-CoV-2 is the causative coronavirus for the disease COVID-19 (<xref rid="B28" ref-type="bibr">28</xref>) which has infected over 46 million people and has led to &gt;1.2 million deaths (worldometers.info/coronavirus: 11/2020). In a recent study of Gordon <italic toggle="yes">et al.</italic> (<xref rid="B29" ref-type="bibr">29</xref>), 26 SARS-CoV-2 proteins have been cloned, tagged and expressed in HEK-293T/17 human cells in order to identify physically interacting proteins with the use of affinity-purification mass spectrometry (AP-MS) technology. Experiments led to the identification of 332 high-confidence protein–protein interactions between the SARS-CoV-2 virus and the human proteins. In addition to this, the study highlights existing drugs which target the human proteins and which can be potentially repurposed and be used for the COVID-19 treatment.</p>
      <p>In more detail, the 2019-nCoV/USA-WA1/2020 SARS-CoV-2 genome (MN985325) was taken from the GenBank database (<xref rid="B30" ref-type="bibr">30</xref>) and was analyzed across its 29 possible open-reading frames (ORFs). The analysis reported 26 annotated protein baits which were found to interact with proteins in human cells. In many cases, these human proteins were found to form protein complexes, reported in the CORUM database (<xref rid="B31" ref-type="bibr">31</xref>). In addition, functional enrichment analysis reported Gene Ontology (GO) biological process terms (<xref rid="B32" ref-type="bibr">32</xref>), collected from the Molecular Signature Database (<xref rid="B33" ref-type="bibr">33</xref>). Interacting drugs with both viral and human proteins were identified through literature searching for targets and pathways, as well as based on cheminformatics searches in the 2020 IUPHAR/BPS Guide to Pharmacology (<xref rid="B34" ref-type="bibr">34</xref>) and the ChEMBL25 (<xref rid="B35" ref-type="bibr">35</xref>) databases.</p>
      <p>In order to combine the heterogeneous information from this example in a single view, based on the data provided by the Gordon <italic toggle="yes">et al.</italic> study, we constructed a five-level multilayered network with Arena3D<sup>web</sup> (Figure <xref rid="F3" ref-type="fig">3</xref>). In detail, these layers are: (i) human proteins and their interactions, (ii) protein complexes these proteins belong to, (iii) biological processes these proteins are involved in, (iv) SARS-CoV-2 proteins and their interactions with the human proteins and (v) possibly repurposable drugs and their respective targets in both the SARS-CoV-2 and human protein layers. To create a more comprehensive view, we treated the different layers as one network and aligned them via the Kamada-Kawai layout. Drugs on the last layer were grouped using a local circular layout and FDA-approved drugs were marked in a cerulean color.</p>
      <fig position="float" id="F3">
        <label>Figure 3.</label>
        <caption>
          <p>A multilayered COVID-19 related example based on the work of Gordon <italic toggle="yes">et al.</italic> Nodes are placed on five different layers (SARS-CoV-2 proteins, drugs, human proteins, protein complexes, biological processes). The vertices are aligned across every layer via the Kamada–Kawai layout algorithm. Two of the most interesting multilayer paths of this study are highlighted in green and pink colors respectively. With green color, pevonedistat directly targets the CUL2 protein complex and the SARS-CoV-2 ORF10 protein. With pink color, zotatifin directly targets eIF4 human proteins and the SARS-CoV-2 NSP2 protein. The latter indirectly interacts both with protein members of the nuclear pore and fibrillin complexes as well as with SARS-CoV-2 NSP9 and ORF6 proteins.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="gkab278fig3" position="float"/>
      </fig>
      <p>We focused on pevonedistat and zotatifin drugs as they target several SARV-CoV-2 proteins as well as certain human protein complexes. We highlight the inter-layer paths these drugs belong to with green and pink colors respectively as well as their protein targets and their distinct complexes. For better visualization, on the human protein layer, we applied the local circular layout where necessary.</p>
      <p>With an at-a-glance view, we observe that the SARS-CoV-2 ORF10 ubiquitin ligase interacts with members from the cullin-2 (CUL2) RING E3 ligase complex and more specifically with the CUL2<sup>ZYG11B</sup> complex. Either ORF10 binds to the CUL2<sup>ZYG11B</sup> complex and hijacks it for ubiquitination and degradation of restriction factors, or ZYG11B binds to the N-terminal glycine in ORF10 and targets it for degradation (<xref rid="B36" ref-type="bibr">36</xref>). Pevonedistat is a NEDD8-activating enzyme (<xref rid="B37" ref-type="bibr">37</xref>) that allows the neddylation of CUL2, a process which is required for transfering ubiquitin to substrates (<xref rid="B38" ref-type="bibr">38</xref>). Therefore, pevonedistat may inhibit the ubiquitination of host proteins that is caused when ORF10 hijacks the CUL2<sup>ZYG11B</sup> complex.</p>
      <p>In general, coronaviruses produce their proteins via cap-dependent mRNA translation (<xref rid="B39" ref-type="bibr">39</xref>). Eukaryotic translation initiation factors 4 (eIF4) are proteins that, as their name implies, act as initiation factors for the translational process (<xref rid="B40" ref-type="bibr">40</xref>). Key eIF4F–cap binding components are attractive candidates for potential coronavirus treatments (<xref rid="B41" ref-type="bibr">41</xref>,<xref rid="B42" ref-type="bibr">42</xref>). Zotatifin directly targets the SARS-CoV-2 NSP2 protein as well as the eIF4H and eIF4E2 human proteins. Specifically, Gordon <italic toggle="yes">et al.</italic> observed a strong antiviral effect through zotatifin, which inhibits eIF4A, a partner of eIF4H. Through the eIF4A inhibition, zotatifin may prevent the translation of a viral 5′ region by impeding its unwinding. The eIF4H human protein also interacts with the viral protein NSP9. Subsequently, NSP9 interacts with human proteins that belong to the nuclear pore and fibrillin protein complexes. Furthermore, the nuclear pore NUP98–RAE1 sub-complex was found to interact with the SARS-CoV-2 ORF6 protein. ORF6 perturbs nuclear transport in order to antagonize host interferon signalling in SARS-CoV (<xref rid="B43" ref-type="bibr">43</xref>). In SARS-CoV-2, the NUP98–RAE1-ORF6 interaction may have a similar effect.</p>
      <p>Pevonedistat and zotatifin both target key human proteins that interact with SARS-CoV-2 proteins, as well as viral proteins which in turn interact with distinct human protein complexes. Since there are no overlaps among the targets of the aforementioned drugs, a cotherapy of the two should be further evaluated as a potential treatment against symptoms of COVID-19.</p>
    </sec>
    <sec id="SEC3-2">
      <title>GPCR signaling pathways implicated in melanoma: a case study</title>
      <p>G-protein coupled receptors (GPCRs) are one of the largest and most diverse superfamilies of cell-surface receptors in eukaryotic organisms. They regulate the majority of cell responses related to signaling stimuli and have been implicated in a wide range of diseases. As a result, today GPCRs are targets for more than 30% of drugs on the market (<xref rid="B44" ref-type="bibr">44</xref>). Most GPCR functions are conducted through heterotrimeric G-proteins, composed by Gα subunits and Gβγ heterodimers, which act as molecular switches that modulate intracellular signaling cascades as responses to receptor activation (<xref rid="B45" ref-type="bibr">45</xref>). G-proteins are grouped, based on the Gα subunit, in four families, Gα<sub>s</sub>, Gα<sub>i/o</sub>, Gα<sub>q/11</sub> and Gα<sub>12/13</sub>. They regulate the function of a wide and diverse range of effector proteins, including several enzymes, regulators of protein function, chaperones, transcription factors and cytoskeletal components. However, other signaling pathways also exist, either complementary to or independent from G-protein signaling. Phosphorylation of GPCRs by a special class of kinases, known as G-protein coupled receptor kinases (GRKs), leads to the internalization of the receptors; the internalized GPCRs can subsequently initiate signaling pathways regulating the expression of genes that control cell growth and/or apoptosis (<xref rid="B46" ref-type="bibr">46</xref>). Another example is GPCR oligomerization; a phenomenon during which multiple GPCRs form supramolecular homo- or hetero-complexes, leading to diverse signal transduction mechanisms (<xref rid="B47" ref-type="bibr">47</xref>). Finally, several GPCRs have been found to directly interact with effectors such as ion channels. All of the aforementioned signaling mechanisms result in complex and diverse signaling networks for GPCRs, with a single receptor capable of regulating a large number of pathways and therefore, a wide range of cell functions (<xref rid="B48" ref-type="bibr">48</xref>).</p>
      <p>GPCR signaling can be deregulated in cancer; either due to damaging mutations affecting the receptors themselves or due to changes in proteins participating in the receptors’ signaling pathways. As a result, many GPCRs constitute attractive pharmacological targets for cancer management and treatment (<xref rid="B49" ref-type="bibr">49</xref>). A characteristic example for a type of cancer with GPCRs as potential pharmacological targets is the malignant melanoma (<xref rid="B50" ref-type="bibr">50</xref>). Melanoma is a type of skin cancer that develops from melanocytes, melanin-producing cells primarily located in the stratum basale, the bottom layer of the skin's epidermis. It is one of the most dangerous types of skin cancer; while it is highly treatable if detected early. Advanced melanoma can spread to the lymph nodes and internal organs (<xref rid="B51" ref-type="bibr">51</xref>). A promising treatment involves the signaling pathways of endothelins, a group of peptide hormones (<xref rid="B52" ref-type="bibr">52–54</xref>). Endothelin signaling is conducted through two GPCRs, the endothelin receptors A and B (EDNRA and EDNRB, respectively). The two GPCRs have been implicated in various types of cancer (<xref rid="B50" ref-type="bibr">50</xref>) and the use of endothelin antagonists has been found to diminish cancer cells <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic>, with both receptors having an impact (<xref rid="B52" ref-type="bibr">52</xref>). However, while in several types of cancer both EDNRA and EDNRB are promising drug targets, in the case of melanoma, EDNRB targeting seems to have a more profound impact upon cancer progression compared to EDNRA (<xref rid="B54" ref-type="bibr">54</xref>).</p>
      <p>To analyze the signaling pathways of EDNRA and EDNRB and show the importance of the latter in melanoma, we constructed a multilayered interaction network (Figure <xref rid="F4" ref-type="fig">4</xref>). Initial interaction evidence for GPCR-related signaling in skin melanocytes was retrieved from hGPCRnet, a web application which allows the tissue-specific visualization and analysis of GPCR signal transduction networks, based on gene expression evidence on different tissues and cell types (<xref rid="B48" ref-type="bibr">48</xref>). The initial skin melanocyte network was then filtered to retrieve the signaling pathways of EDNRA and EDNRB, as well as all the related protein-protein interactions, which were subsequently used to construct a 3D representation in Arena3D<sup>web</sup>. The GPCR signaling network obtained is organized in four distinct layers: the top layer includes the receptors; namely, EDNRA and EDNRB. The two intermediate layers represent G-proteins and GRKs, for the intermediate steps of the G-protein and phosphorylation/internalization signaling pathways, respectively. Finally, the bottom layer contains all effectors that are regulated from the aforementioned pathways. Visual inspection of the EDNRA–EDNRB network (Figure <xref rid="F4" ref-type="fig">4</xref>) reveals a rather complex signaling network for the two receptors. The network consists of a total of 331 interactions; these include not only inter-layer links (e.g. GPCR–G-protein, G-protein–effector contacts), representing the different steps of the signaling pathways, but also intra-layer contacts, particularly in the effectors layer, as many effectors form supramolecular complexes with one-another to achieve a common cell response (e.g. tubulin subunits organize to microtubules). The edges representing the signaling pathways of the two receptors have been colored using red for the pathways unique to EDNRA, blue for the pathways unique to EDNRB and green for pathways controlled by both receptors.</p>
      <fig position="float" id="F4">
        <label>Figure 4.</label>
        <caption>
          <p>Overview of the EDNRA–EDNRB endothelin receptor signaling network. Nodes are placed in four different layers representing the different hierarchical levels in GPCR signaling (GPCRs, GRKs, G-proteins and effectors). The inter-layer edges representing the signaling pathways of the two receptors have been colored using red for the pathways unique to EDNRA, blue for the pathways unique to EDNRB and green for pathways controlled by both receptors. Intra-layer edges, connecting proteins in the same hierarchical level (e.g. effector–effector interactions) are colored gray. Effectors with clinical relevance to melanoma (CDH1, MAP3K5 etc.) are shown bigger and colored magenta.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="gkab278fig4" position="float"/>
      </fig>
      <p>Inspection of the EDNRA–EDNRB signaling network reveals that the vast majority of endothelin-related cell responses in skin melanocytes are controlled by both receptors. Activated EDNRA and EDNRB both interact with three major G-protein subunits, GNAI1, GNAI2 and GNAI3, belonging to the Gα<sub>i/o</sub> family; through these, the two GPCRs control the formation of cytoskeletal components by influencing the functionality of α-, β- and γ-tubulins (TUBA1A, TUBA1B, TUBB1, TUBG1 etc.), the folding and maturation of proteins through interactions with chaperones such as HSP90-β (HSP90AB1), and the mechanisms of apoptosis and cell death through the control of apoptotic factors such as TNF-associated factor 6 (TRAF6) and the PTEN phosphatase (PTEN). Positive or negative disruption of the aforementioned processes can lead to the uncontrolled cell growth/multiplication or cell death, respectively; thus, showcasing the importance of both receptors in various types of cancer. At the same time, both receptors interact with GNA11, a member of the Gα<sub>q</sub> family, which controls the function of Phospholipase C (PLCB2). The latter is an enzyme that initiates signaling cascades of second messenger molecules that regulate protein kinase C (PKC) and in turn, control the MAPK kinase pathway (MAP3K5). The MAPK pathway is typically deregulated in melanoma; therefore, inhibitors for key members of that pathway have been used for treatment in the past (<xref rid="B55" ref-type="bibr">55</xref>).</p>
      <p>However, while EDNRA’s signaling mechanisms are mostly limited to the above, a number of pathways exist that are unique to EDNRB. These feature interactions of the receptor with all members of the Gα<sub>q/11</sub> family (GNAQ, GNA11, GNA13 and GNA14), which also control PLCβ and MAPK. EDNRB controls the activation of the phosphatidylinositol 3 kinases (PIKC3A and PIK3CB); these effectors play a key role in inducing drug resistance after treatment in melanoma patients and are, therefore, a decisive target for novel drug design in melanoma therapy (<xref rid="B56" ref-type="bibr">56</xref>). Another pathway includes the regulation of Rho Guanine Exchange Factors (RhoGEFs). EDNRB, through GNAQ and GNA13, regulates the function of RhoGEFs 1 (ARHGEF1), 11 (ARHGEF11) and 12 (ARHGEF12); these effectors regulate the enzyme activity of Rho GTPases that control the movement and morphology of melanoma cells (<xref rid="B57" ref-type="bibr">57</xref>). Finally, EDNRB controls the function of Cadherin-1 (CDH1), a regulator of cell adhesion and a tumor suppressor in melanoma (<xref rid="B58" ref-type="bibr">58</xref>). Overall, the aforementioned pathways show that while both GPCRs control a number of functions and cell mechanisms related to the progression of cancer in general and melanoma in particular, including the MAPK pathway, EDNRB exclusively regulates a number of additional signaling mechanisms that are specific to this type of cancer and is, therefore, a more suitable target for the design of anti-melanoma treatments.</p>
    </sec>
  </sec>
  <sec sec-type="discussion" id="SEC4">
    <title>DISCUSSION</title>
    <p>To avoid confusion, while Arena3D<sup>web</sup> has been inspired by the Arena3D standalone version, it is a new application which has been written from scratch using different technologies. Compared to Arena3D, Arena3D<sup>web</sup> comes with a much richer functionality and navigation options. A characteristic example is its greater variety of layout algorithms which can be used very efficiently and in multiple ways. The most advanced feature in Arena3D<sup>web</sup> is the possibility to apply the layout algorithms to a subset of layers or the whole network. This allows us to generate views with much less line crossovers and makes it easier to detect feature patterns. Furthermore, as a web server application, Arena3D<sup>web</sup> can run on any browser and attract a much broader audience beyond the biomedical field. On the contrary, Arena3D comes with many library dependencies, could run only on Windows and Linux and was bound to certain Java and OpenGL versions as well to the outdated Java3D library. Finally, Arena3D<sup>web</sup> comes with a more flexible input file format as well as with a more advanced export function to save and re-import the status of a network at any time.</p>
    <p>Concerning scalability, in its online version, Arena3D<sup>web</sup> can handle networks of up to 5000 nodes. This limitation can be bypassed when running the application locally, by adjusting the <italic toggle="yes">max_allowed_edges</italic> variable value in the global.R file. We tested Arena3D<sup>web</sup> on a 32GB RAM, 6-core processor @ 4.2 GHz, AMD Radeon RX 5700 XT desktop machine. We ran the application on all platforms (Unix, Windows, MacOS) using a network consisting of 1600 nodes and 2396 edges. We tested the application on Rstudio, Mozilla Firefox, Google Chrome, Microsoft Edge and Safari and benchmarked its memory and CPU requirements. We observed that Arena3D<sup>web</sup> consumed ∼300–500MB RAM on Edge browser and ∼1–1.5GB RAM on Chrome, Firefox and Rstudio (including the memory needed by each browser). Due to a memory leak, on Windows systems, Mozilla Firefox kept exhausting the memory during execution, an issue which might have been evoked by a conflict between Firefox and the WebGL renderer. This problem does not occur when running Firefox on Linux. The memory requirements on MacOS across all three browsers was significantly lower (∼200MB for Chrome and Safari and ∼500MB for Firefox). In addition, enabling hardware acceleration on a browser helps in achieving smoother 3D transformations. Hence, a CPU load reduction from ∼50% to ∼13% was observed when visualizing the aforementioned network at 30 frames per seconds (FPS). Furthermore, the navigation controls run smoother on any of the browsers compared to RStudio, and therefore Unix and MacOS users are encouraged to run Arena3D<sup>web</sup> on any of those. Windows users are encouraged to run Arena3D<sup>web</sup> on Microsoft Edge which was found to be the most memory efficient. Finally, due to the heavy 3D transformations and calculations the performance might become a bit slower, especially in computers with weaker graphics cards or limited processing power. For such scenarios, we offer a notable performance increase by pausing the rendering of inter-layer edges when applying 3D scene transformations (e.g. dragging, rotations). To further increase the performance, one can disable the ‘<italic toggle="yes">Edge Width By Weight</italic>’ option and set the inter-layer edge opacities to zero in order to stop their rendering throughout usage.</p>
    <p>Overall, due to its ease-of-use, simplicity and interoperability, we expect Arena3D<sup>web</sup> to become the reference tool for multilayer graph analysis and visualization.</p>
  </sec>
  <sec sec-type="data-availability" id="SEC5">
    <title>DATA AVAILABILITY</title>
    <p>Arena3D<sup>web</sup> is an open-source application. Its code can be downloaded from the GitHub repository: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/PavlopoulosLab/Arena3Dweb" ext-link-type="uri">https://github.com/PavlopoulosLab/Arena3Dweb</ext-link>. The service is available online at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://bib.fleming.gr/Arena3D" ext-link-type="uri">http://bib.fleming.gr/Arena3D</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://bib.fleming.gr:3838/Arena3D" ext-link-type="uri">http://bib.fleming.gr:3838/Arena3D</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://bib.fleming.gr:8080/Arena3D" ext-link-type="uri">http://bib.fleming.gr:8080/Arena3D</ext-link> or <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://bib.fleming.gr:8084/Arena3D" ext-link-type="uri">http://bib.fleming.gr:8084/Arena3D</ext-link></p>
  </sec>
</body>
<back>
  <ack id="ACK1">
    <title>ACKNOWLEDGEMENTS</title>
    <p><italic toggle="yes">Author contributions</italic>: E.K. wrote the code and implemented the tool. F.B. generated all the necessary data related to the case studies. N.A.P. benchmarked the tool. R.S. conceived new concepts which make Arena3D<sup>web</sup> more accessible than Arena3D. G.A.P. conceived the idea and supervised the whole project from the beginning to its end. All authors wrote parts of the article.</p>
  </ack>
  <sec id="SEC6">
    <title>FUNDING</title>
    <p>Hellenic Foundation for Research and Innovation (H.F.R.I.) under the ‘First Call for H.F.R.I. Research Projects to support faculty members and researchers and the procurement of high-cost research equipment grant’ [1855-BOLOGNA]. Funding for open access charge: Hellenic Foundation for Research and Innovation (H.F.R.I.) under the “First Call for H.F.R.I. Research Projects to support faculty members and researchers and the procurement of high-cost research equipment grant” [1855-BOLOGNA].</p>
    <p><italic toggle="yes">Conflict of interest statement</italic>. None declared.</p>
  </sec>
  <notes id="NT1">
    <title>Notes</title>
    <p>Present address: Georgios A. Pavlopoulos, Institute for Fundamental Biomedical Research, BSRC “Alexander Fleming”, 34 Fleming Street, Vari, 16672, Greece.</p>
  </notes>
  <ref-list id="REF1">
    <title>REFERENCES</title>
    <ref id="B1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Koutrouli</surname><given-names>M.</given-names></string-name>, <string-name><surname>Karatzas</surname><given-names>E.</given-names></string-name>, <string-name><surname>Paez-Espino</surname><given-names>D.</given-names></string-name>, <string-name><surname>Pavlopoulos</surname><given-names>G.A.</given-names></string-name></person-group><article-title>A guide to conquer the biological network era using graph theory</article-title>. <source>Front. Bioeng. Biotechnol.</source><year>2020</year>; <volume>8</volume>:<fpage>34</fpage>.<pub-id pub-id-type="pmid">32083072</pub-id></mixed-citation>
    </ref>
    <ref id="B2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Doncheva</surname><given-names>N.T.</given-names></string-name>, <string-name><surname>Assenov</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Domingues</surname><given-names>F.S.</given-names></string-name>, <string-name><surname>Albrecht</surname><given-names>M.</given-names></string-name></person-group><article-title>Topological analysis and interactive visualization of biological networks and protein structures</article-title>. <source>Nat. Protoc.</source><year>2012</year>; <volume>7</volume>:<fpage>670</fpage>–<lpage>685</lpage>.<pub-id pub-id-type="pmid">22422314</pub-id></mixed-citation>
    </ref>
    <ref id="B3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pavlopoulos</surname><given-names>G.A.</given-names></string-name>, <string-name><surname>Paez-Espino</surname><given-names>D.</given-names></string-name>, <string-name><surname>Kyrpides</surname><given-names>N.C.</given-names></string-name>, <string-name><surname>Iliopoulos</surname><given-names>I.</given-names></string-name></person-group><article-title>Empirical comparison of visualization tools for larger-scale network analysis</article-title>. <source>Adv. Bioinforma.</source><year>2017</year>; <volume>2017</volume>:<fpage>1278932</fpage>.</mixed-citation>
    </ref>
    <ref id="B4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pavlopoulos</surname><given-names>G.A.</given-names></string-name>, <string-name><surname>Wegener</surname><given-names>A.-L.</given-names></string-name>, <string-name><surname>Schneider</surname><given-names>R.</given-names></string-name></person-group><article-title>A survey of visualization tools for biological network analysis</article-title>. <source>BioData Min.</source><year>2008</year>; <volume>1</volume>:<fpage>12</fpage>.<pub-id pub-id-type="pmid">19040716</pub-id></mixed-citation>
    </ref>
    <ref id="B5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gehlenborg</surname><given-names>N.</given-names></string-name>, <string-name><surname>O’Donoghue</surname><given-names>S.I.</given-names></string-name>, <string-name><surname>Baliga</surname><given-names>N.S.</given-names></string-name>, <string-name><surname>Goesmann</surname><given-names>A.</given-names></string-name>, <string-name><surname>Hibbs</surname><given-names>M.A.</given-names></string-name>, <string-name><surname>Kitano</surname><given-names>H.</given-names></string-name>, <string-name><surname>Kohlbacher</surname><given-names>O.</given-names></string-name>, <string-name><surname>Neuweger</surname><given-names>H.</given-names></string-name>, <string-name><surname>Schneider</surname><given-names>R.</given-names></string-name>, <string-name><surname>Tenenbaum</surname><given-names>D.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Visualization of omics data for systems biology</article-title>. <source>Nat. Methods</source>. <year>2010</year>; <volume>7</volume>:<fpage>S56</fpage>–<lpage>S68</lpage>.<pub-id pub-id-type="pmid">20195258</pub-id></mixed-citation>
    </ref>
    <ref id="B6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shannon</surname><given-names>P.</given-names></string-name>, <string-name><surname>Markiel</surname><given-names>A.</given-names></string-name>, <string-name><surname>Ozier</surname><given-names>O.</given-names></string-name>, <string-name><surname>Baliga</surname><given-names>N.S.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>J.T.</given-names></string-name>, <string-name><surname>Ramage</surname><given-names>D.</given-names></string-name>, <string-name><surname>Amin</surname><given-names>N.</given-names></string-name>, <string-name><surname>Schwikowski</surname><given-names>B.</given-names></string-name>, <string-name><surname>Ideker</surname><given-names>T.</given-names></string-name></person-group><article-title>Cytoscape: a software environment for integrated models of biomolecular interaction networks</article-title>. <source>Genome Res.</source><year>2003</year>; <volume>13</volume>:<fpage>2498</fpage>–<lpage>2504</lpage>.<pub-id pub-id-type="pmid">14597658</pub-id></mixed-citation>
    </ref>
    <ref id="B7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Franz</surname><given-names>M.</given-names></string-name>, <string-name><surname>Lopes</surname><given-names>C.T.</given-names></string-name>, <string-name><surname>Huck</surname><given-names>G.</given-names></string-name>, <string-name><surname>Dong</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Sumer</surname><given-names>O.</given-names></string-name>, <string-name><surname>Bader</surname><given-names>G.D.</given-names></string-name></person-group><article-title>Cytoscape.js: a graph theory library for visualisation and analysis</article-title>. <source>Bioinforma. Oxf. Engl.</source><year>2016</year>; <volume>32</volume>:<fpage>309</fpage>–<lpage>311</lpage>.</mixed-citation>
    </ref>
    <ref id="B8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Szklarczyk</surname><given-names>D.</given-names></string-name>, <string-name><surname>Morris</surname><given-names>J.H.</given-names></string-name>, <string-name><surname>Cook</surname><given-names>H.</given-names></string-name>, <string-name><surname>Kuhn</surname><given-names>M.</given-names></string-name>, <string-name><surname>Wyder</surname><given-names>S.</given-names></string-name>, <string-name><surname>Simonovic</surname><given-names>M.</given-names></string-name>, <string-name><surname>Santos</surname><given-names>A.</given-names></string-name>, <string-name><surname>Doncheva</surname><given-names>N.T.</given-names></string-name>, <string-name><surname>Roth</surname><given-names>A.</given-names></string-name>, <string-name><surname>Bork</surname><given-names>P.</given-names></string-name><etal>et al</etal>.</person-group><article-title>The STRING database in 2017: quality-controlled protein–protein association networks, made broadly accessible</article-title>. <source>Nucleic Acids Res.</source><year>2017</year>; <volume>45</volume>:<fpage>D362</fpage>–<lpage>D368</lpage>.<pub-id pub-id-type="pmid">27924014</pub-id></mixed-citation>
    </ref>
    <ref id="B9">
      <label>9.</label>
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Koutrouli</surname><given-names>M.</given-names></string-name>, <string-name><surname>Karatzas</surname><given-names>E.</given-names></string-name>, <string-name><surname>Papanikolopoulou</surname><given-names>K.</given-names></string-name>, <string-name><surname>Pavlopoulos</surname><given-names>G.A.</given-names></string-name></person-group><article-title>NORMA–the network makeup artist: a web tool for network annotation visualization</article-title>. <year>2020</year>; <comment>bioRxiv doi:</comment><comment>05 March 2020, preprint: not peer reviewed</comment><pub-id pub-id-type="doi">10.1101/2020.03.05.978585</pub-id>.</mixed-citation>
    </ref>
    <ref id="B10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bastian</surname><given-names>M.</given-names></string-name>, <string-name><surname>Heymann</surname><given-names>S.</given-names></string-name>, <string-name><surname>Jacomy</surname><given-names>M.</given-names></string-name></person-group><article-title>Gephi: an open source software for exploring and manipulating networks</article-title>. <source>Proceedings of the International AAAI Conference on Web and Social Media</source>. <year>2009</year>; <volume>3</volume>:<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.gephi.org/users/publications/">https://gephi.org/users/publications/</uri>.</mixed-citation>
    </ref>
    <ref id="B11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mrvar</surname><given-names>A.</given-names></string-name>, <string-name><surname>Batagelj</surname><given-names>V.</given-names></string-name></person-group><article-title>Analysis and visualization of large networks with program package Pajek</article-title>. <source>Complex Adapt. Syst. Model.</source><year>2016</year>; <volume>4</volume>:<fpage>6</fpage>.</mixed-citation>
    </ref>
    <ref id="B12">
      <label>12.</label>
      <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Auber</surname><given-names>D.</given-names></string-name>, <string-name><surname>Archambault</surname><given-names>D.</given-names></string-name>, <string-name><surname>Bourqui</surname><given-names>R.</given-names></string-name>, <string-name><surname>Delest</surname><given-names>M.</given-names></string-name>, <string-name><surname>Dubois</surname><given-names>J.</given-names></string-name>, <string-name><surname>Lambert</surname><given-names>A.</given-names></string-name>, <string-name><surname>Mary</surname><given-names>P.</given-names></string-name>, <string-name><surname>Mathiaut</surname><given-names>M.</given-names></string-name>, <string-name><surname>Melançon</surname><given-names>G.</given-names></string-name>, <string-name><surname>Pinaud</surname><given-names>B.</given-names></string-name><etal>et al</etal>.</person-group><person-group person-group-type="editor"><string-name><surname>Alhajj</surname><given-names>R.</given-names></string-name>, <string-name><surname>Rokne</surname><given-names>J.</given-names></string-name></person-group><article-title>Tulip 5</article-title>. <source>Encyclopedia of Social Network Analysis and Mining</source>. <year>2017</year>; <publisher-loc>NY</publisher-loc><publisher-name>Springer New York</publisher-name><fpage>1</fpage>–<lpage>28</lpage>.</mixed-citation>
    </ref>
    <ref id="B13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Theocharidis</surname><given-names>A.</given-names></string-name>, <string-name><surname>van Dongen</surname><given-names>S.</given-names></string-name>, <string-name><surname>Enright</surname><given-names>A.J.</given-names></string-name>, <string-name><surname>Freeman</surname><given-names>T.C.</given-names></string-name></person-group><article-title>Network visualization and analysis of gene expression data using BioLayout Express(3D)</article-title>. <source>Nat. Protoc.</source><year>2009</year>; <volume>4</volume>:<fpage>1535</fpage>–<lpage>1550</lpage>.<pub-id pub-id-type="pmid">19798086</pub-id></mixed-citation>
    </ref>
    <ref id="B14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>McGee</surname><given-names>F.</given-names></string-name>, <string-name><surname>Ghoniem</surname><given-names>M.</given-names></string-name>, <string-name><surname>Melançon</surname><given-names>G.</given-names></string-name>, <string-name><surname>Otjacques</surname><given-names>B.</given-names></string-name>, <string-name><surname>Pinaud</surname><given-names>B.</given-names></string-name></person-group><article-title>The state of the art in multilayer network visualization</article-title>. <source>Comput. Graph. Forum</source>. <year>2019</year>; <volume>38</volume>:<fpage>125</fpage>–<lpage>149</lpage>.</mixed-citation>
    </ref>
    <ref id="B15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pavlopoulos</surname><given-names>G.A.</given-names></string-name>, <string-name><surname>O’Donoghue</surname><given-names>S.I.</given-names></string-name>, <string-name><surname>Satagopam</surname><given-names>V.P.</given-names></string-name>, <string-name><surname>Soldatos</surname><given-names>T.G.</given-names></string-name>, <string-name><surname>Pafilis</surname><given-names>E.</given-names></string-name>, <string-name><surname>Schneider</surname><given-names>R.</given-names></string-name></person-group><article-title>Arena3D: visualization of biological networks in 3D</article-title>. <source>BMC Syst. Biol.</source><year>2008</year>; <volume>2</volume>:<fpage>104</fpage>.<pub-id pub-id-type="pmid">19040715</pub-id></mixed-citation>
    </ref>
    <ref id="B16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Secrier</surname><given-names>M.</given-names></string-name>, <string-name><surname>Pavlopoulos</surname><given-names>G.A.</given-names></string-name>, <string-name><surname>Aerts</surname><given-names>J.</given-names></string-name>, <string-name><surname>Schneider</surname><given-names>R.</given-names></string-name></person-group><article-title>Arena3D: visualizing time-driven phenotypic differences in biological systems</article-title>. <source>BMC Bioinformatics</source>. <year>2012</year>; <volume>13</volume>:<fpage>45</fpage>.<pub-id pub-id-type="pmid">22439608</pub-id></mixed-citation>
    </ref>
    <ref id="B17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Škrlj</surname><given-names>B.</given-names></string-name>, <string-name><surname>Kralj</surname><given-names>J.</given-names></string-name>, <string-name><surname>Lavrač</surname><given-names>N.</given-names></string-name></person-group><article-title>Py3plex toolkit for visualization and analysis of multilayer networks</article-title>. <source>Appl. Netw. Sci.</source><year>2019</year>; <volume>4</volume>:<fpage>94</fpage>.</mixed-citation>
    </ref>
    <ref id="B18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hammoud</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Kramer</surname><given-names>F.</given-names></string-name></person-group><article-title>mully: an R package to create, modify and visualize multilayered graphs</article-title>. <source>Genes</source>. <year>2018</year>; <volume>9</volume>:<fpage>519</fpage>.</mixed-citation>
    </ref>
    <ref id="B19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>De Domenico</surname><given-names>M.</given-names></string-name>, <string-name><surname>Porter</surname><given-names>M.A.</given-names></string-name>, <string-name><surname>Arenas</surname><given-names>A.</given-names></string-name></person-group><article-title>MuxViz: a tool for multilayer analysis and visualization of networks</article-title>. <source>J. Complex Netw.</source><year>2015</year>; <volume>3</volume>:<fpage>159</fpage>–<lpage>176</lpage>.</mixed-citation>
    </ref>
    <ref id="B20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Csardi</surname><given-names>G.</given-names></string-name>, <string-name><surname>Nepusz</surname><given-names>T.</given-names></string-name></person-group><article-title>The igraph software package for complex network research</article-title>. <source>InterJournal Complex Syst.</source><year>2006</year>; <volume>1695</volume>:<fpage>1</fpage>–<lpage>9</lpage>.</mixed-citation>
    </ref>
    <ref id="B21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Reingold</surname><given-names>E.M.</given-names></string-name>, <string-name><surname>Tilford</surname><given-names>J.S.</given-names></string-name></person-group><article-title>Tidier drawings of trees</article-title>. <source>IEEE Trans. Softw. Eng.</source><year>1981</year>; <volume>SE-7</volume>:<fpage>223</fpage>–<lpage>228</lpage>.</mixed-citation>
    </ref>
    <ref id="B22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fruchterman</surname><given-names>T.M.J.</given-names></string-name>, <string-name><surname>Reingold</surname><given-names>E.M.</given-names></string-name></person-group><article-title>Graph drawing by force-directed placement</article-title>. <source>Softw. Pract. Exp.</source><year>1991</year>; <volume>21</volume>:<fpage>1129</fpage>–<lpage>1164</lpage>.</mixed-citation>
    </ref>
    <ref id="B23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Davidson</surname><given-names>R.</given-names></string-name>, <string-name><surname>Harel</surname><given-names>D.</given-names></string-name></person-group><article-title>Drawing graphs nicely using simulated annealing</article-title>. <source>ACM Trans. Graph.</source><year>1996</year>; <volume>15</volume>:<fpage>301</fpage>–<lpage>331</lpage>.</mixed-citation>
    </ref>
    <ref id="B24">
      <label>24.</label>
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Bryan</surname><given-names>M.</given-names></string-name>, <string-name><surname>Shawn Brown</surname><given-names>W.M.</given-names></string-name>, <string-name><surname>Klavans</surname><given-names>R.</given-names></string-name>, <string-name><surname>Boyack</surname><given-names>K.W.</given-names></string-name></person-group><article-title>Dr.L: distributed recursive (Graph) layout</article-title>. <year>2008</year>; <comment>No. dRl; 002182MLTPL00. Sandia National Laboratories, 2007</comment><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.osti.gov/biblio/1231060">https://www.osti.gov/biblio/1231060</uri>.</mixed-citation>
    </ref>
    <ref id="B25">
      <label>25.</label>
      <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Cox</surname><given-names>T.F.</given-names></string-name>, <string-name><surname>Cox</surname><given-names>M.A.A.</given-names></string-name></person-group><source>Multidimensional Scaling</source>. <year>2001</year>; <edition>2nd edn</edition><publisher-loc>Boca Raton</publisher-loc><publisher-name>Chapman &amp; Hall/CRC</publisher-name>.</mixed-citation>
    </ref>
    <ref id="B26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kamada</surname><given-names>T.</given-names></string-name>, <string-name><surname>Kawai</surname><given-names>S.</given-names></string-name></person-group><article-title>An algorithm for drawing general undirected graphs</article-title>. <source>Inf. Process. Lett.</source><year>1989</year>; <volume>31</volume>:<fpage>7</fpage>–<lpage>15</lpage>.</mixed-citation>
    </ref>
    <ref id="B27">
      <label>27.</label>
      <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Frick</surname><given-names>A.</given-names></string-name>, <string-name><surname>Ludwig</surname><given-names>A.</given-names></string-name>, <string-name><surname>Mehldau</surname><given-names>H.</given-names></string-name></person-group><person-group person-group-type="editor"><string-name><surname>Tamassia</surname><given-names>R.</given-names></string-name>, <string-name><surname>Tollis</surname><given-names>I.G.</given-names></string-name></person-group><article-title>A fast adaptive layout algorithm for undirected graphs (extended abstract and system demonstration)</article-title>. <source>Graph Drawing, Lecture Notes in Computer Science</source>. <year>1995</year>; <volume>894</volume>:<publisher-loc>Berlin, Heidelberg</publisher-loc><publisher-name>Springer Berlin Heidelberg</publisher-name><fpage>388</fpage>–<lpage>403</lpage>.</mixed-citation>
    </ref>
    <ref id="B28">
      <label>28.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cevik</surname><given-names>M.</given-names></string-name>, <string-name><surname>Kuppalli</surname><given-names>K.</given-names></string-name>, <string-name><surname>Kindrachuk</surname><given-names>J.</given-names></string-name>, <string-name><surname>Peiris</surname><given-names>M.</given-names></string-name></person-group><article-title>Virology, transmission, and pathogenesis of SARS-CoV-2</article-title>. <source>BMJ</source>. <year>2020</year>; <volume>371</volume>:<fpage>m3862</fpage>.<pub-id pub-id-type="pmid">33097561</pub-id></mixed-citation>
    </ref>
    <ref id="B29">
      <label>29.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gordon</surname><given-names>D.E.</given-names></string-name>, <string-name><surname>Jang</surname><given-names>G.M.</given-names></string-name>, <string-name><surname>Bouhaddou</surname><given-names>M.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Obernier</surname><given-names>K.</given-names></string-name>, <string-name><surname>White</surname><given-names>K.M.</given-names></string-name>, <string-name><surname>O’Meara</surname><given-names>M.J.</given-names></string-name>, <string-name><surname>Rezelj</surname><given-names>V.V.</given-names></string-name>, <string-name><surname>Guo</surname><given-names>J.Z.</given-names></string-name>, <string-name><surname>Swaney</surname><given-names>D.L.</given-names></string-name><etal>et al</etal>.</person-group><article-title>A SARS-CoV-2 protein interaction map reveals targets for drug repurposing</article-title>. <source>Nature</source>. <year>2020</year>; <volume>583</volume>:<fpage>459</fpage>–<lpage>468</lpage>.<pub-id pub-id-type="pmid">32353859</pub-id></mixed-citation>
    </ref>
    <ref id="B30">
      <label>30.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Clark</surname><given-names>K.</given-names></string-name>, <string-name><surname>Karsch-Mizrachi</surname><given-names>I.</given-names></string-name>, <string-name><surname>Lipman</surname><given-names>D.J.</given-names></string-name>, <string-name><surname>Ostell</surname><given-names>J.</given-names></string-name>, <string-name><surname>Sayers</surname><given-names>E.W.</given-names></string-name></person-group><article-title>GenBank</article-title>. <source>Nucleic Acids Res.</source><year>2016</year>; <volume>44</volume>:<fpage>D67</fpage>–<lpage>D72</lpage>.<pub-id pub-id-type="pmid">26590407</pub-id></mixed-citation>
    </ref>
    <ref id="B31">
      <label>31.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Giurgiu</surname><given-names>M.</given-names></string-name>, <string-name><surname>Reinhard</surname><given-names>J.</given-names></string-name>, <string-name><surname>Brauner</surname><given-names>B.</given-names></string-name>, <string-name><surname>Dunger-Kaltenbach</surname><given-names>I.</given-names></string-name>, <string-name><surname>Fobo</surname><given-names>G.</given-names></string-name>, <string-name><surname>Frishman</surname><given-names>G.</given-names></string-name>, <string-name><surname>Montrone</surname><given-names>C.</given-names></string-name>, <string-name><surname>Ruepp</surname><given-names>A.</given-names></string-name></person-group><article-title>CORUM: the comprehensive resource of mammalian protein complexes—2019</article-title>. <source>Nucleic Acids Res.</source><year>2019</year>; <volume>47</volume>:<fpage>D559</fpage>–<lpage>D563</lpage>.<pub-id pub-id-type="pmid">30357367</pub-id></mixed-citation>
    </ref>
    <ref id="B32">
      <label>32.</label>
      <mixed-citation publication-type="journal"><collab>Gene Ontology Consortium</collab><article-title>The Gene Ontology (GO) database and informatics resource</article-title>. <source>Nucleic Acids Res.</source><year>2004</year>; <volume>32</volume>:<fpage>D258</fpage>–<lpage>D261</lpage>.<pub-id pub-id-type="pmid">14681407</pub-id></mixed-citation>
    </ref>
    <ref id="B33">
      <label>33.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liberzon</surname><given-names>A.</given-names></string-name>, <string-name><surname>Subramanian</surname><given-names>A.</given-names></string-name>, <string-name><surname>Pinchback</surname><given-names>R.</given-names></string-name>, <string-name><surname>Thorvaldsdottir</surname><given-names>H.</given-names></string-name>, <string-name><surname>Tamayo</surname><given-names>P.</given-names></string-name>, <string-name><surname>Mesirov</surname><given-names>J.P.</given-names></string-name></person-group><article-title>Molecular signatures database (MSigDB) 3.0</article-title>. <source>Bioinformatics</source>. <year>2011</year>; <volume>27</volume>:<fpage>1739</fpage>–<lpage>1740</lpage>.<pub-id pub-id-type="pmid">21546393</pub-id></mixed-citation>
    </ref>
    <ref id="B34">
      <label>34.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Armstrong</surname><given-names>J.F.</given-names></string-name>, <string-name><surname>Faccenda</surname><given-names>E.</given-names></string-name>, <string-name><surname>Harding</surname><given-names>S.D.</given-names></string-name>, <string-name><surname>Pawson</surname><given-names>A.J.</given-names></string-name>, <string-name><surname>Southan</surname><given-names>C.</given-names></string-name>, <string-name><surname>Sharman</surname><given-names>J.L.</given-names></string-name>, <string-name><surname>Campo</surname><given-names>B.</given-names></string-name>, <string-name><surname>Cavanagh</surname><given-names>D.R.</given-names></string-name>, <string-name><surname>Alexander</surname><given-names>S.P.H.</given-names></string-name>, <string-name><surname>Davenport</surname><given-names>A.P.</given-names></string-name><etal>et al</etal>.</person-group><article-title>The IUPHAR/BPS Guide to PHARMACOLOGY in 2020: extending immunopharmacology content and introducing the IUPHAR/MMV Guide to MALARIA PHARMACOLOGY</article-title>. <source>Nucleic Acids Res.</source><year>2019</year>; <volume>48</volume>:<fpage>D1006</fpage>–<lpage>D1021</lpage>.</mixed-citation>
    </ref>
    <ref id="B35">
      <label>35.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gaulton</surname><given-names>A.</given-names></string-name>, <string-name><surname>Bellis</surname><given-names>L.J.</given-names></string-name>, <string-name><surname>Bento</surname><given-names>A.P.</given-names></string-name>, <string-name><surname>Chambers</surname><given-names>J.</given-names></string-name>, <string-name><surname>Davies</surname><given-names>M.</given-names></string-name>, <string-name><surname>Hersey</surname><given-names>A.</given-names></string-name>, <string-name><surname>Light</surname><given-names>Y.</given-names></string-name>, <string-name><surname>McGlinchey</surname><given-names>S.</given-names></string-name>, <string-name><surname>Michalovich</surname><given-names>D.</given-names></string-name>, <string-name><surname>Al-Lazikani</surname><given-names>B.</given-names></string-name><etal>et al</etal>.</person-group><article-title>ChEMBL: a large-scale bioactivity database for drug discovery</article-title>. <source>Nucleic Acids Res.</source><year>2012</year>; <volume>40</volume>:<fpage>D1100</fpage>–<lpage>D1107</lpage>.<pub-id pub-id-type="pmid">21948594</pub-id></mixed-citation>
    </ref>
    <ref id="B36">
      <label>36.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Timms</surname><given-names>R.T.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Rhee</surname><given-names>D.Y.</given-names></string-name>, <string-name><surname>Harper</surname><given-names>J.W.</given-names></string-name>, <string-name><surname>Koren</surname><given-names>I.</given-names></string-name>, <string-name><surname>Elledge</surname><given-names>S.J.</given-names></string-name></person-group><article-title>A glycine-specific N-degron pathway mediates the quality control of protein N-myristoylation</article-title>. <source>Science</source>. <year>2019</year>; <volume>365</volume>:<fpage>eaaw4912</fpage>.<pub-id pub-id-type="pmid">31273098</pub-id></mixed-citation>
    </ref>
    <ref id="B37">
      <label>37.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Czuczman</surname><given-names>N.M.</given-names></string-name>, <string-name><surname>Barth</surname><given-names>M.J.</given-names></string-name>, <string-name><surname>Gu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Neppalli</surname><given-names>V.</given-names></string-name>, <string-name><surname>Mavis</surname><given-names>C.</given-names></string-name>, <string-name><surname>Frys</surname><given-names>S.E.</given-names></string-name>, <string-name><surname>Hu</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>S.</given-names></string-name>, <string-name><surname>Klener</surname><given-names>P.</given-names></string-name>, <string-name><surname>Vockova</surname><given-names>P.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo</article-title>. <source>Blood</source>. <year>2016</year>; <volume>127</volume>:<fpage>1128</fpage>–<lpage>1137</lpage>.<pub-id pub-id-type="pmid">26675347</pub-id></mixed-citation>
    </ref>
    <ref id="B38">
      <label>38.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Soucy</surname><given-names>T.A.</given-names></string-name>, <string-name><surname>Smith</surname><given-names>P.G.</given-names></string-name>, <string-name><surname>Milhollen</surname><given-names>M.A.</given-names></string-name>, <string-name><surname>Berger</surname><given-names>A.J.</given-names></string-name>, <string-name><surname>Gavin</surname><given-names>J.M.</given-names></string-name>, <string-name><surname>Adhikari</surname><given-names>S.</given-names></string-name>, <string-name><surname>Brownell</surname><given-names>J.E.</given-names></string-name>, <string-name><surname>Burke</surname><given-names>K.E.</given-names></string-name>, <string-name><surname>Cardin</surname><given-names>D.P.</given-names></string-name>, <string-name><surname>Critchley</surname><given-names>S.</given-names></string-name><etal>et al</etal>.</person-group><article-title>An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer</article-title>. <source>Nature</source>. <year>2009</year>; <volume>458</volume>:<fpage>732</fpage>–<lpage>736</lpage>.<pub-id pub-id-type="pmid">19360080</pub-id></mixed-citation>
    </ref>
    <ref id="B39">
      <label>39.</label>
      <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Nakagawa</surname><given-names>K.</given-names></string-name>, <string-name><surname>Lokugamage</surname><given-names>K.G.</given-names></string-name>, <string-name><surname>Makino</surname><given-names>S.</given-names></string-name></person-group><article-title>Viral and cellular mRNA translation in coronavirus-infected cells</article-title>. <source>Advances in Virus Research</source>. <year>2016</year>; <volume>96</volume>:<publisher-name>Elsevier</publisher-name><fpage>165</fpage>–<lpage>192</lpage>.<pub-id pub-id-type="pmid">27712623</pub-id></mixed-citation>
    </ref>
    <ref id="B40">
      <label>40.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gingras</surname><given-names>A.-C.</given-names></string-name>, <string-name><surname>Raught</surname><given-names>B.</given-names></string-name>, <string-name><surname>Sonenberg</surname><given-names>N.</given-names></string-name></person-group><article-title>eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation</article-title>. <source>Annu. Rev. Biochem.</source><year>1999</year>; <volume>68</volume>:<fpage>913</fpage>–<lpage>963</lpage>.<pub-id pub-id-type="pmid">10872469</pub-id></mixed-citation>
    </ref>
    <ref id="B41">
      <label>41.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Müller</surname><given-names>C.</given-names></string-name>, <string-name><surname>Schulte</surname><given-names>F.W.</given-names></string-name>, <string-name><surname>Lange-Grünweller</surname><given-names>K.</given-names></string-name>, <string-name><surname>Obermann</surname><given-names>W.</given-names></string-name>, <string-name><surname>Madhugiri</surname><given-names>R.</given-names></string-name>, <string-name><surname>Pleschka</surname><given-names>S.</given-names></string-name>, <string-name><surname>Ziebuhr</surname><given-names>J.</given-names></string-name>, <string-name><surname>Hartmann</surname><given-names>R.K.</given-names></string-name>, <string-name><surname>Grünweller</surname><given-names>A.</given-names></string-name></person-group><article-title>Broad-spectrum antiviral activity of the eIF4A inhibitor silvestrol against corona- and picornaviruses</article-title>. <source>Antiviral Res.</source><year>2018</year>; <volume>150</volume>:<fpage>123</fpage>–<lpage>129</lpage>.<pub-id pub-id-type="pmid">29258862</pub-id></mixed-citation>
    </ref>
    <ref id="B42">
      <label>42.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cencic</surname><given-names>R.</given-names></string-name>, <string-name><surname>Desforges</surname><given-names>M.</given-names></string-name>, <string-name><surname>Hall</surname><given-names>D.R.</given-names></string-name>, <string-name><surname>Kozakov</surname><given-names>D.</given-names></string-name>, <string-name><surname>Du</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Min</surname><given-names>J.</given-names></string-name>, <string-name><surname>Dingledine</surname><given-names>R.</given-names></string-name>, <string-name><surname>Fu</surname><given-names>H.</given-names></string-name>, <string-name><surname>Vajda</surname><given-names>S.</given-names></string-name>, <string-name><surname>Talbot</surname><given-names>P.J.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Blocking eIF4E-eIF4G Interaction as a Strategy To Impair Coronavirus Replication</article-title>. <source>J. Virol.</source><year>2011</year>; <volume>85</volume>:<fpage>6381</fpage>–<lpage>6389</lpage>.<pub-id pub-id-type="pmid">21507972</pub-id></mixed-citation>
    </ref>
    <ref id="B43">
      <label>43.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Frieman</surname><given-names>M.</given-names></string-name>, <string-name><surname>Yount</surname><given-names>B.</given-names></string-name>, <string-name><surname>Heise</surname><given-names>M.</given-names></string-name>, <string-name><surname>Kopecky-Bromberg</surname><given-names>S.A.</given-names></string-name>, <string-name><surname>Palese</surname><given-names>P.</given-names></string-name>, <string-name><surname>Baric</surname><given-names>R.S.</given-names></string-name></person-group><article-title>Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum/Golgi membrane</article-title>. <source>J. Virol.</source><year>2007</year>; <volume>81</volume>:<fpage>9812</fpage>–<lpage>9824</lpage>.<pub-id pub-id-type="pmid">17596301</pub-id></mixed-citation>
    </ref>
    <ref id="B44">
      <label>44.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rosenbaum</surname><given-names>D.M.</given-names></string-name>, <string-name><surname>Rasmussen</surname><given-names>S.G.F.</given-names></string-name>, <string-name><surname>Kobilka</surname><given-names>B.K.</given-names></string-name></person-group><article-title>The structure and function of G-protein-coupled receptors</article-title>. <source>Nature</source>. <year>2009</year>; <volume>459</volume>:<fpage>356</fpage>–<lpage>363</lpage>.<pub-id pub-id-type="pmid">19458711</pub-id></mixed-citation>
    </ref>
    <ref id="B45">
      <label>45.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Oldham</surname><given-names>W.M.</given-names></string-name>, <string-name><surname>Hamm</surname><given-names>H.E.</given-names></string-name></person-group><article-title>Heterotrimeric G protein activation by G-protein-coupled receptors</article-title>. <source>Nat. Rev. Mol. Cell Biol.</source><year>2008</year>; <volume>9</volume>:<fpage>60</fpage>–<lpage>71</lpage>.<pub-id pub-id-type="pmid">18043707</pub-id></mixed-citation>
    </ref>
    <ref id="B46">
      <label>46.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gurevich</surname><given-names>E.V.</given-names></string-name>, <string-name><surname>Tesmer</surname><given-names>J.J.G.</given-names></string-name>, <string-name><surname>Mushegian</surname><given-names>A.</given-names></string-name>, <string-name><surname>Gurevich</surname><given-names>V.V.</given-names></string-name></person-group><article-title>G protein-coupled receptor kinases: more than just kinases and not only for GPCRs</article-title>. <source>Pharmacol. Ther.</source><year>2012</year>; <volume>133</volume>:<fpage>40</fpage>–<lpage>69</lpage>.<pub-id pub-id-type="pmid">21903131</pub-id></mixed-citation>
    </ref>
    <ref id="B47">
      <label>47.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Casadó</surname><given-names>V.</given-names></string-name>, <string-name><surname>Cortés</surname><given-names>A.</given-names></string-name>, <string-name><surname>Mallol</surname><given-names>J.</given-names></string-name>, <string-name><surname>Pérez-Capote</surname><given-names>K.</given-names></string-name>, <string-name><surname>Ferré</surname><given-names>S.</given-names></string-name>, <string-name><surname>Lluis</surname><given-names>C.</given-names></string-name>, <string-name><surname>Franco</surname><given-names>R.</given-names></string-name>, <string-name><surname>Canela</surname><given-names>E.I.</given-names></string-name></person-group><article-title>GPCR homomers and heteromers: a better choice as targets for drug development than GPCR monomers</article-title>. <source>Pharmacol. Ther.</source><year>2009</year>; <volume>124</volume>:<fpage>248</fpage>–<lpage>257</lpage>.<pub-id pub-id-type="pmid">19664655</pub-id></mixed-citation>
    </ref>
    <ref id="B48">
      <label>48.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Apostolakou</surname><given-names>A.E.</given-names></string-name>, <string-name><surname>Baltoumas</surname><given-names>F.A.</given-names></string-name>, <string-name><surname>Stravopodis</surname><given-names>D.J.</given-names></string-name>, <string-name><surname>Iconomidou</surname><given-names>V.A.</given-names></string-name></person-group><article-title>Extended human G-protein coupled receptor network: cell-type-specific analysis of G-protein coupled receptor signaling pathways</article-title>. <source>J. Proteome Res.</source><year>2020</year>; <volume>19</volume>:<fpage>511</fpage>–<lpage>524</lpage>.<pub-id pub-id-type="pmid">31774292</pub-id></mixed-citation>
    </ref>
    <ref id="B49">
      <label>49.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lappano</surname><given-names>R.</given-names></string-name>, <string-name><surname>Maggiolini</surname><given-names>M.</given-names></string-name></person-group><article-title>G protein-coupled receptors: novel targets for drug discovery in cancer</article-title>. <source>Nat. Rev. Drug Discov.</source><year>2011</year>; <volume>10</volume>:<fpage>47</fpage>–<lpage>60</lpage>.<pub-id pub-id-type="pmid">21193867</pub-id></mixed-citation>
    </ref>
    <ref id="B50">
      <label>50.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lee</surname><given-names>H.J.</given-names></string-name>, <string-name><surname>Wall</surname><given-names>B.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>S.</given-names></string-name></person-group><article-title>G-protein-coupled receptors and melanoma</article-title>. <source>Pigment Cell Melanoma Res.</source><year>2008</year>; <volume>21</volume>:<fpage>415</fpage>–<lpage>428</lpage>.<pub-id pub-id-type="pmid">18582227</pub-id></mixed-citation>
    </ref>
    <ref id="B51">
      <label>51.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Siegel</surname><given-names>R.L.</given-names></string-name>, <string-name><surname>Miller</surname><given-names>K.D.</given-names></string-name>, <string-name><surname>Jemal</surname><given-names>A.</given-names></string-name></person-group><article-title>Cancer statistics, 2019</article-title>. <source>CA. Cancer J. Clin.</source><year>2019</year>; <volume>69</volume>:<fpage>7</fpage>–<lpage>34</lpage>.<pub-id pub-id-type="pmid">30620402</pub-id></mixed-citation>
    </ref>
    <ref id="B52">
      <label>52.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rosanò</surname><given-names>L.</given-names></string-name>, <string-name><surname>Spinella</surname><given-names>F.</given-names></string-name>, <string-name><surname>Bagnato</surname><given-names>A.</given-names></string-name></person-group><article-title>Endothelin 1 in cancer: biological implications and therapeutic opportunities</article-title>. <source>Nat. Rev. Cancer</source>. <year>2013</year>; <volume>13</volume>:<fpage>637</fpage>–<lpage>651</lpage>.<pub-id pub-id-type="pmid">23884378</pub-id></mixed-citation>
    </ref>
    <ref id="B53">
      <label>53.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Saldana-Caboverde</surname><given-names>A.</given-names></string-name>, <string-name><surname>Kos</surname><given-names>L.</given-names></string-name></person-group><article-title>Roles of endothelin signaling in melanocyte development and melanoma: Endothelins in melanocyte development and melanoma</article-title>. <source>Pigment Cell Melanoma Res.</source><year>2010</year>; <volume>23</volume>:<fpage>160</fpage>–<lpage>170</lpage>.<pub-id pub-id-type="pmid">20128875</pub-id></mixed-citation>
    </ref>
    <ref id="B54">
      <label>54.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Smith</surname><given-names>M.P.</given-names></string-name>, <string-name><surname>Rowling</surname><given-names>E.J.</given-names></string-name>, <string-name><surname>Miskolczi</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Ferguson</surname><given-names>J.</given-names></string-name>, <string-name><surname>Spoerri</surname><given-names>L.</given-names></string-name>, <string-name><surname>Haass</surname><given-names>N.K.</given-names></string-name>, <string-name><surname>Sloss</surname><given-names>O.</given-names></string-name>, <string-name><surname>McEntegart</surname><given-names>S.</given-names></string-name>, <string-name><surname>Arozarena</surname><given-names>I.</given-names></string-name>, <string-name><surname>Kriegsheim</surname><given-names>A.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure</article-title>. <source>EMBO Mol. Med.</source><year>2017</year>; <volume>9</volume>:<fpage>1011</fpage>–<lpage>1029</lpage>.<pub-id pub-id-type="pmid">28606996</pub-id></mixed-citation>
    </ref>
    <ref id="B55">
      <label>55.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Urtatiz</surname><given-names>O.</given-names></string-name>, <string-name><surname>Van Raamsdonk</surname><given-names>C.D.</given-names></string-name></person-group><article-title>Gnaq and Gna11 in the endothelin signaling pathway and melanoma</article-title>. <source>Front. Genet.</source><year>2016</year>; <volume>7</volume>:<fpage>59</fpage>.<pub-id pub-id-type="pmid">27148356</pub-id></mixed-citation>
    </ref>
    <ref id="B56">
      <label>56.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Davies</surname><given-names>M.A.</given-names></string-name></person-group><article-title>The role of the PI3K-AKT pathway in melanoma</article-title>. <source>Cancer J. Sudbury Mass</source>. <year>2012</year>; <volume>18</volume>:<fpage>142</fpage>–<lpage>147</lpage>.</mixed-citation>
    </ref>
    <ref id="B57">
      <label>57.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sanz-Moreno</surname><given-names>V.</given-names></string-name>, <string-name><surname>Marshall</surname><given-names>C.J.</given-names></string-name></person-group><article-title>Rho-GTPase signaling drives melanoma cell plasticity</article-title>. <source>Cell Cycle Georget. Tex</source>. <year>2009</year>; <volume>8</volume>:<fpage>1484</fpage>–<lpage>1487</lpage>.</mixed-citation>
    </ref>
    <ref id="B58">
      <label>58.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hsu</surname><given-names>M.Y.</given-names></string-name>, <string-name><surname>Meier</surname><given-names>F.E.</given-names></string-name>, <string-name><surname>Nesbit</surname><given-names>M.</given-names></string-name>, <string-name><surname>Hsu</surname><given-names>J.Y.</given-names></string-name>, <string-name><surname>Van Belle</surname><given-names>P.</given-names></string-name>, <string-name><surname>Elder</surname><given-names>D.E.</given-names></string-name>, <string-name><surname>Herlyn</surname><given-names>M.</given-names></string-name></person-group><article-title>E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors</article-title>. <source>Am. J. Pathol.</source><year>2000</year>; <volume>156</volume>:<fpage>1515</fpage>–<lpage>1525</lpage>.<pub-id pub-id-type="pmid">10793063</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
